Evidence map›Paper›PMID 25462529›Full record

ArticleMolecular therapy. Nucleic acids2014

Comparison Between Several Integrase-defective Lentiviral Vectors Reveals Increased Integration of an HIV Vector Bearing a D167H Mutant.

Muhammad Qamar Saeed, Noelle Dufour, Cynthia Bartholmae, Urzula Sieranska, Malaika Knopf, Eloïse Thierry, Sylvain Thierry, Olivier Delelis, Nicolas Grandchamp, Héloïse Pilet and 8 more

Open access · goldAbstract read
In one paragraph

Article in Molecular therapy. Nucleic acids, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 3 countries.

Muhammad Qamar Saeed1] CEA, DSV, IBM, Molecular Imaging Research Center (MIRCen), Fontenay-aux-Roses, France [2] INSERM, UMS27, Fontenay-aux-Roses, France [3] Institute of Pure and Applied Biology, Microbiology Division, Bahauddin Zakariya University Multan, Pakistan.
Noelle Dufour1] CEA, DSV, IBM, Molecular Imaging Research Center (MIRCen), Fontenay-aux-Roses, France [2] Laboratoire des maladies neurodégénératives CNRS, CEA URA 2210.
Cynthia BartholmaeDepartment of Translasional Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Urzula SieranskaCEA, Laboratoire des Cellules Souches Hématopoïétiques et Leucémiques, (IRCM), Fontenay-aux-Roses, France.
Malaika KnopfDepartment of Translasional Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Eloïse ThierryEBIM, Ecole Normale Supérieure de Cachan, Cachan, Paris, France.
Sylvain ThierryEBIM, Ecole Normale Supérieure de Cachan, Cachan, Paris, France.
Olivier DelelisEBIM, Ecole Normale Supérieure de Cachan, Cachan, Paris, France.
Nicolas GrandchampNewVectys, Villebon-sur-Yvette, France.
Héloïse PiletNewVectys, Villebon-sur-Yvette, France.
Philippe RavassardICM-BBL, CNRS UMR 7225, Hôpital Pitié-Salpêtrière, Paris, France.
Julie Massonneau1] CEA, DSV, IBM, Molecular Imaging Research Center (MIRCen), Fontenay-aux-Roses, France [2] INSERM, UMS27, Fontenay-aux-Roses, France.
Françoise PflumioCEA, Laboratoire des Cellules Souches Hématopoïétiques et Leucémiques, (IRCM), Fontenay-aux-Roses, France.
Christof von KalleDepartment of Translasional Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
François Lachapelle1] CEA, DSV, IBM, Molecular Imaging Research Center (MIRCen), Fontenay-aux-Roses, France [2] INSERM, UMS27, Fontenay-aux-Roses, France.
Alexis-Pierre Bemelmans1] CEA, DSV, IBM, Molecular Imaging Research Center (MIRCen), Fontenay-aux-Roses, France [2] Laboratoire des maladies neurodégénératives CNRS, CEA URA 2210.
Manfred SchmidtDepartment of Translasional Oncology, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Ché Serguera1] CEA, DSV, IBM, Molecular Imaging Research Center (MIRCen), Fontenay-aux-Roses, France [2] INSERM, UMS27, Fontenay-aux-Roses, France.
École Normale Supérieure Paris-Saclay · FRNational Center for Tumor Diseases · DECEA Paris-Saclay - Etablissement de Fontenay-aux-roses · FRCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRInserm · FRInstitut des Maladies Neurodégénératives · FRHeidelberg University · DEPitié-Salpêtrière Hospital · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HIV-1 derived vectors are among the most efficient for gene transduction in mammalian tissues. As the parent virus, they carry out vector genome insertion into the host cell chromatin. Consequently, their preferential integration in transcribed genes raises several conceptual and safety issues. To address part of these questions, HIV-derived vectors have been engineered to be nonintegrating. This was mainly achieved by mutating HIV-1 integrase at functional hotspots of the enzyme enabling the development of streamlined nuclear DNA circles functional for transgene expression. Few integrase mutant vectors have been successfully tested so far for gene transfer. They are cleared with time in mitotic cells, but stable within nondividing retina cells or neurons. Here, we compared six HIV vectors carrying different integrases, either wild type or with different mutations (D64V, D167H, Q168A, K186Q+Q214L+Q216L, and RRK262-264AAH) shown to modify integrase enzymatic activity, oligomerization, or interaction with key cellular cofactor of HIV DNA integration as LEDGF/p75 or TNPO3. We show that these mutations differently affect the transduction efficiency as well as rates and patterns of integration of HIV-derived vectors suggesting their different processing in the nucleus. Surprisingly and most interestingly, we report that an integrase carrying the D167H substitution improves vector transduction efficiency and integration in both HEK-293T and primary CD34+ cells.

Identifiers

PMID25462529
PMCPMC4272407
OpenAlexW2060420367

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.